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Background: The Consolidated Standards of Reporting Trials (CONSORT) Statement is intended to facilitate better
reporting of randomised clinical trials (RCTs). A systematic review recently published in the Cochrane Library
assesses whether journal endorsement of CONSORT impacts the completeness of reporting of RCTs; those findings
are summarised here.
Methods: Evaluations assessing the completeness of reporting of RCTs based on any of 27 outcomes formulated
based on the 1996 or 2001 CONSORT checklists were included; two primary comparisons were evaluated. The 27
outcomes were: the 22 items of the 2001 CONSORT checklist, four sub-items describing blinding and a ‘total
summary score’ of aggregate items, as reported. Relative risks (RR) and 99% confidence intervals were calculated to
determine effect estimates for each outcome across evaluations.
Results: Fifty-three reports describing 50 evaluations of 16,604 RCTs were assessed for adherence to at least one of
27 outcomes. Sixty-nine of 81 meta-analyses show relative benefit from CONSORT endorsement on completeness
of reporting. Between endorsing and non-endorsing journals, 25 outcomes are improved with CONSORT
endorsement, five of these significantly (α = 0.01). The number of evaluations per meta-analysis was often low with
substantial heterogeneity; validity was assessed as low or unclear for many evaluations.
Conclusions: The results of this review suggest that journal endorsement of CONSORT may benefit the
completeness of reporting of RCTs they publish. No evidence suggests that endorsement hinders the completeness
of RCT reporting. However, despite relative improvements when CONSORT is endorsed by journals, the
completeness of reporting of trials remains sub-optimal. Journals are not sending a clear message about
endorsement to authors submitting manuscripts for publication. As such, fidelity of endorsement as an
‘intervention’ has been weak to date. Journals need to take further action regarding their endorsement and
implementation of CONSORT to facilitate accurate, transparent and complete reporting of trials.
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In the mid-1990s, in response to concerns about the
quality of reporting of randomised controlled trials
(RCTs), an international group of trialists, statisticians,
epidemiologists and biomedical editors developed The
CONsolidated Standards Of Reporting Trials (CON-
SORT) Statement [1], which has been revised and
updated twice [2,3], each with a companion explanatory
document [4,5]. The Statement is an evidence-based
minimum set of recommendations, consisting of a
checklist, flow diagram and descriptive text, intended to
facilitate the complete and transparent reporting of
RCTs and subsequently aid in their critical appraisal and
interpretation. Over time, evidence of the impact of
CONSORT has accumulated. It is one of the most
widely cited scientific contributions of all time (over
5,300 citations, not including self-citation). CONSORT
has also been rated as one of the major milestones in
health research methods over the last century by the
Patient-Centered Outcomes Research Institute (PCORI)
[6]. The most recent version, CONSORT 2010 is among
the top 1% of article-level content contained in the Pub-
lic Library of Science (http://www.plos.org/). Its use has
been endorsed by international organisations of editors
such as the International Committee of Medical Journal
Editors (ICMJE), the World Association of Medical Edi-
tors (WAME), and the Committee On Publication Ethics
(COPE). Over 600 general and specialty journals cur-
rently endorse the CONSORT Statement [7].
‘Endorsement’ of CONSORT by a journal is defined as
any of the following situations, which imply that the
CONSORT Statement is, at least, in principle incorpo-
rated into the editorial process of the journal: (a) journal
editorial statement endorsing the CONSORT Statement:
either the flow diagram, the checklist or both; (b) re-
quirement or recommendation in journal’s ‘Instructions
to Authors’ to follow CONSORT when preparing their
manuscript; or (c) requirement for authors to submit a
CONSORT checklist and/or flow diagram with their
manuscript. At this time, information with regards to
the regulation and enforcement of use and adherence to
CONSORT by editors is too sparse to incorporate in this
review. Complete reporting was assessed by comparing
the proportion of RCTs adhering to individual CON-
SORT items, blinding subgroups or by total scores
across CONSORT checklist items termed ‘Total sum
score’.
Along with the publication of the 2001 version of
CONSORT, Moher and colleagues reported an evalu-
ation of the CONSORT checklist [8]. The authors
reported that the completeness of reports of RCTs in
three CONSORT endorsing journals was higher than
one non-endorsing journal. Since then, additional eva-
luations have been published which assess the influenceof CONSORT either directly or indirectly. In 2006 a sys-
tematic review identified eight evaluations that assessed
the completeness of reporting in medical journals that
did or did not formally endorse CONSORT [9]. Despite
methodological weaknesses of included evaluations, the
2006 systematic review found that the use of CONSORT
may improve the quality of reporting of RCTs.
Objective
This paper provides a comprehensive summary of the
91-page report of the updated systematic review asses-
sing the influence of CONSORT, published in the
Cochrane Library [10]. The objective of the update was
to assess whether journal endorsement of the CON-
SORT Statement is associated with improved complete-
ness of reporting of RCTs.
Methods
Electronic database searches were performed to update
the 2006 systematic review for the time period January
2005 to March 2010, inclusive, searched on 27 May
2010. The end search date was purposely selected to ex-
clude the date of publication of the most recent CON-
SORT Statement (CONSORT 2010) as it was not
expected it to have been in use for a sufficient period to
have produced evaluations.
MEDLINE (via OVID), EMBASE (via OVID), the
Cochrane Methodology Register and the Cochrane Data-
base of Systematic Reviews, both using the Wiley inter-
face, were searched using a comprehensive strategy [10].
The following citation indices were also searched using
the ISI Web of Knowledge interface: The Science Cit-
ation Index, Social Science Citation Index, and Arts and
Humanities Citation Index. Electronic records were
stored and managed online through systematic review
data management software, DistillerSRW [11].
Studies were included in the review if they evaluated
the completeness of reporting of RCTs, and could be
included in any of the following comparison groups, by
assessing the: (1) completeness of reporting assessed in
RCTs published in CONSORT-endorsing journals com-
pared to non-endorsing journals; (2) completeness of
reporting of RCTs published in CONSORT endorsing
journals before and after endorsement; or (3) complete-
ness of reporting of RCTs before and after the publica-
tion of the 1996 or 2001 CONSORT Statement. Studies
were not excluded based on language of publication or
validity assessment. The CONSORT checklist is being
endorsed by non-medical journals, typically in veterinary
trials [12], such ‘non-human’ trial evaluations were not
eligible for this review.
When the eligibility of studies was either unclear or
the data reported were insufficient to categorize the
study into at least one of the reviews’ pre-specified
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tacted for clarification and invited to submit unpublished
data. This enabled judgment about study eligibility and,
if eligible, provided data which were extracted for meta-
analyses, when possible. For example, if the citations for
RCTs included in an evaluation were provided, review
authors could determine endorsement status of their
publishing journals at the time of RCT publication by
checking a journal’s Instructions to Authors and/or con-
tacting editors of journals. A journal was considered an
endorser if it had endorsed CONSORT at least months
prior to publication of the evaluated RCT.
Title, abstract and full text screening of potentially
relevant records was completed by two independent
reviewers. One reviewer extracted general study charac-
teristics of included studies, with complete verification
by a second reviewer. Data on the completeness of
reporting were extracted by one reviewer; a second re-
viewer verified accuracy of a 10% random sample. Dis-
crepancies were resolved by discussion between the two
reviewers or arbitration with a third member of the re-
search team, when necessary. No modifications to the
extracted data were made post-verification. Validity of
included studies was assessed by one reviewer with
complete verification by a second reviewer using pre-
specified criteria [10].
Data on 27 outcomes were collected to estimate com-
pleteness of reporting of RCTs in included evaluations.
These were: any of the 22 items on the 2001 CONSORT
checklist, any of four additional sub-items for blinding
(outcome assessor, intervention, patients and data ana-
lyst), or ‘Total Sum Score’ (that is, an aggregate score of
some or all CONSORT checklist items). While data ex-
traction was based on items of the 2001 CONSORT
checklist, where studies evaluated the 1996 checklist,
analyses were sub-grouped by checklist year since some
checklist items were known to have undergone substan-
tial modification in the 1996 to 2001 CONSORT update.
These items were: ‘Title and Abstract’, ‘Outcomes’, ‘Sam-
ple Size’, ‘Participant Flow’ and ‘Numbers Analysed’ [10].
Relative proportions of RCTs adequately reporting any
of the 27 outcomes were extracted from included stud-
ies. In addition, if quality of RCTs within included eva-
luations was assessed using a quality assessment tool
however measured (for example, Jadad scale [13]), these
data were extracted.
Relative risks (RR) and 99% confidence intervals were
calculated to determine effect estimates for each outcome
across evaluations. Reported mean scores across some or
all checklist items, described as a ‘Total Sum Score’ were
also pooled where a standardised mean difference (SMD)
greater than zero indicates more complete reporting
among RCTs published in CONSORT-endorsing
journals.Results
The electronic searches retrieved a total of 4,777
records; two additional reports were identified. In
addition, eight reports were included in the 2006 sys-
tematic review. Duplicate records were removed, and
the titles and abstracts of the remaining 2,896 records
were screened yielding 632 potentially relevant studies.
Full text screening identified 53 reports of 50 evaluations
(Figure 1). Two of the three comparison groups include
evaluations where more information is known about en-
dorsement of CONSORT as a more direct intervention.
Subsequently, we report the findings of these two com-
parison groups, ‘CONSORT endorsing journals com-
pared to non-endorsing journals’ and ‘CONSORT
endorsing journals before and after’. Please refer to the
Cochrane review for results of the third comparison
group, cross-sectional samples of RCTs before and after
the publication of the CONSORT Statement.
CONSORT-endorsing journals compared to non-endorsing
journals
Twenty-nine (of 53) evaluations were eligible for this com-
parison group. Across the 27 outcomes the number of
studies per meta-analysis varied (median (IQR1, IQR3), 6
[5,8]). Adequate reporting of the method of ‘Allocation
Concealment’ and the description of flow of participants
through the trial, ‘Participant Flow’, had the largest number
of included studies (n=16), evaluating adequacy of report-
ing in 2,396 and 2,140 RCTs, respectively.
Of 27 outcomes evaluated, 25 had effect estimates in-
dicating a relatively higher proportion of completely
reported RCTs published in CONSORT-endorsing jour-
nals compared to non-endorsing journals. Of these, five
were statistically significant at the 1% level (Figure 2);
adequate details of method of ‘Allocation Concealment’
RR = 1.81 (1.25, 2.61) (16 evaluations, 2,396 RCTs, I2= 75%).
This suggests that 81% more RCTs published in
CONSORT-endorsing journals described allocation conceal-
ment more completely compared to those published in non-
endorsing journals.
Other outcomes which resulted in statistically signifi-
cant effects, favouring the completeness of reporting in
CONSORT-endorsing journals were providing an ad-
equate scientific explanation and rationale detailed in
the ‘Introduction’ of the trial, RR = 1.07 (1.01, 1.14) (five
evaluations, 513 RCTs, I2 = 0%), adequate description of
how ‘Sample Size’ was determined RR = 1.61 (1.13, 2.29)
(11 evaluations, 1,843 RCTs, I2 = 76%), and adequate de-
scription of the method used for ‘Sequence Generation’
RR = 1.59 (1.38, 1.84) (14 evaluations, 2,231 RCTs, I2 =
24%). Seven included studies evaluating 560 RCTs con-
tributed to a statistically significant pooled effect in
favour of CONSORT for ‘Total Sum Score’: SMD = 0.68
(0.38, 0.98) (I2 = 0%). This indicates that when adequate
Figure 1 PRISMA flow diagram.
Turner et al. Systematic Reviews 2012, 1:60 Page 4 of 7
http://www.systematicreviewsjournal.com/content/1/1/60reporting was summarised across all CONSORT items,
RCTs published in CONSORT-endorsing journals were
more completely reported than RCTs published in non-
endorsing journals.
Precise details of ‘Interventions’, CONSORT checklist
item four, were equally reported in endorsing and non-
endorsing journals, RR=1.0 (0.95, 1.05) (six evaluations,
638 RCTs, I2 = 0%), and eligibility criteria for trial ‘Parti-
cipants’ was reported in six evaluations assessing a total
of 683 RCTs, and resulted in an effect estimate less than
1.0, RR= 0.95 (0.56, 1.62). This suggests that the relative
completeness of reporting for this item is slightly less in
CONSORT-endorsing journals compared to non-
endorsing journals.
Eight studies were not strictly compliant with the def-
inition of a CONSORT-endorsing journal used in this
review. Sensitivity analyses showed that only one out-
come (of 27), although only minimally different, differedwhen evaluations that did not directly meet our defin-
ition of endorsement were excluded. Completeness of
reporting of the scientific rational and background in
the ‘Introduction’, was adjusted from RR = 1.07 (1.01,
1.14) to 1.05 (0.87, 1.27).
CONSORT-endorsing journals before and after CONSORT
endorsement
Eleven (of 53) evaluations assessed journals that endorse
the CONSORT Statement and presented RCT complete-
ness of reporting of at least one CONSORT item before
and after the journal’s date of endorsement of CON-
SORT. The number of RCTs assessed per outcome had
a median (IQR) of 532 (512, 919). The number of
reported CONSORT checklist items varied over evalua-
tions, with a median (IQR) of 3 (2, 5). Adequate report-
ing of the method of ‘Sequence generation’ and the flow
of participants through the trial, ‘Participant Flow’, were
Figure 2 Pooled relative risks across assessed 2001 CONSORT checklist items with 99% confidence intervals for primary comparison,
adherence of RCTs published in CONSORT-endorsing journals compared to RCTs published in CONSORT non-endorsing journals.
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comes data were reported in fewer than five evaluations.
The results across all outcomes in this comparison are
presented (Figure 3).
Discussion
Serious systemic problems exist in how research is
reported. This is a wasteful use of already limitedFigure 3 Pooled relative risks across assessed 2001 CONSORT checkli
of RCTs published in CONSORT-endorsing journals before and after eresources that fund health research [14]. This issue might
reflect several factors including inadequate conduct, slop-
piness in reporting, and quite possibly an inability of
researchers to clearly and transparently inform readers
about the methods and findings of their research [15]. The
problem is endemic known to affect many, if not all, areas
of healthcare research [16-18]. Systematic reviews evaluat-
ing the effectiveness of health interventions typically relyst items with 99% confidence intervals comparing the adherence
ndorsement.
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[19]. However, the inadequate reporting of essential ele-
ments in these reports hinders the systematic review
process, often leaving reviewers unable to make definitive
conclusions [20].
This review suggests that RCTs which report their
findings using the CONSORT statement as guidance
may produce more complete RCT reports. While this
review provides some important insight into the impact
of CONSORT on completeness of reporting it is not
without limitations. Although the search was completed
more than 2 years ago we do not believe that any new
evaluations would alter the present results as the
included number of evaluations is large and includes
data from over 16,600 trials. The majority of CONSORT
evaluations are small and very large studies with dra-
matic effect estimates would need to be included to
modify the current results. Similarly, newer evaluations
may evaluate the CONSORT 2010 checklist which are
ineligible for this systematic review. None of the
included evaluations utilized an experimental design
(that is, randomised trial) and as such are subject to the
influence of confounding, in particular, potential im-
provement in completeness of reporting over time as
well as discrepant editorial policies between journals.
The inclusion criteria for this review were broad and
variability in methodology, field of interest and validity
between evaluations was considerable. The use of 99%
confidence intervals, intended to estimate conservative
effects given the questionable validity and heterogeneity
of included studies, aims to offer readers with more con-
fidence in the findings of this review, especially those of
statistical significance.
There are inconsistencies in how journals implement
reporting guidelines when reports of RCTs are submit-
ted for publication [21,22]. Since editorial procedures
are not consistently available online, this review was un-
able to assess journal implementation of CONSORT en-
dorsement (that is, verification by the journals’ editorial
team of author adherence to CONSORT). Anecdotally,
there is variability between how verification for CON-
SORT adherence by authors factors into the editorial
decision-making process (if at all) between journals.
Editors may want to use these results develop explicit
statements about their journals’ endorsement of CON-
SORT, and other reporting guidelines, in their ‘Instruc-
tions to Authors’, and optimally to recommend
submission of the CONSORT checklist and flow dia-
gram at the time of manuscript submission [23]. It is
likely that active endorsement policies by journals will
lead to more complete, clear and transparent publica-
tions, ultimately increasing the usability of research
reports to make decisions about healthcare treatment
and services.Conclusions
The results of this review suggest that journal endorse-
ment of CONSORT may benefit the completeness of
reporting of RCTs they publish. No evidence suggests
that endorsement hinders the completeness of RCT
reporting. However, despite relative improvements when
CONSORT is endorsed by journals, the completeness of
reporting of trials remains sub-optimal. Journals are not
sending a clear message about endorsement to authors
submitting manuscripts for publication. As such, fidelity
of endorsement as an ‘intervention’ has been weak to
date. Journals need to take further action regarding their
endorsement and implementation of CONSORT to fa-
cilitate accurate, transparent and complete reporting of
trials.
All CONSORT guidance documents including the
2010 checklist, flow diagram, extension statements and
other resources are freely available from the CONSORT
website [24] and in numerous open-access publications.
Their consistent use and adherence by authors and jour-
nals has the potential to revolutionize the reporting and
subsequent usefulness of RCT reports.
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